Latest News — Page 29

Can pay‑for‑performance be redesigned to reduce health inequalities? ⚖️

This piece shows how equity‑based pricing—using distributional cost‑effectiveness analysis and contract theory—can adjust QOF reimbursement to balance total QALY gains with their distribution across deprivation (IMD) groups, with simulations calibrated to CPRD data demonstrating trade‑offs between efficiency and equity. Targeted higher payments for deprived populations can improve equity (measured by EDE) even when budgets are neutral, offering a practical policy lever to curb under‑provision in deprived areas.

Read the full analysis to see the simulations, calibrated elasticities, and policy recommendations for embedding equity into primary care incentives. 📊

#SyenzaNews #HealthEconomics #HealthcareInnovation #costeffectiveness #healthcarepolicy

Are your clinical studies ready for EU-wide HTA alignment?

The European Commission has opened the first 2026 submission window for Joint Scientific Consultations (Jan 7–Feb 4, 2026) — a free opportunity to get early HTA input (including parallel EMA coordination) that helps design studies fit for Joint Clinical Assessments and smoother market access. Aligning evidence early can cut duplication, reduce assessment delays, and strengthen reimbursement cases.

Read the full article to see key deadlines, submission steps, and practical tips to make the most of JSCs. 🔗

#SyenzaNews #regulatoryaffairs #HealthEconomics #MarketAccess #healthcarepolicy

🚨 Are β-blockers really necessary for heart attack patients with preserved heart function?

A new meta-analysis published in JAMA Cardiology reviews data from nearly 20,000 patients and reveals that these medications do not significantly improve outcomes such as mortality or recurrent events in those with preserved ejection fraction (LVEF ≥50%). This could reshape treatment guidelines in cardiology!

Explore the findings and their implications for post-MI care in this insightful article.

#SyenzaNews #HealthcareInnovation #HealthEconomics

💰 How is Portugal navigating the complexities of Epidyolex spending amid reimbursement delays?

Portugal’s National Health Service has spent over €3 million on the CBD-based epilepsy treatment Epidyolex since 2021, revealing crucial insights into patient access and healthcare costs. This article unpacks the implications for rare epilepsy patients and highlights the challenges facing healthcare allocation in the country.

Dive into the full details to understand how this investment is shaping the future of epilepsy care and the potential impact on healthcare resources.

#SyenzaNews #HealthcareInnovation #HealthEconomics #MarketAccess

🌍 Ready to lead in the rapidly evolving pharmaceutical landscape?

The upcoming Global Pharma Executive Course offers crucial training for industry leaders looking to navigate disruptions and innovate in R&D, supply chain, and patient-centered strategies. Join renowned speakers from top firms like Pfizer and Johnson & Johnson as you enhance your leadership skills and expand your professional network in Portugal, a burgeoning hub for pharma education.

Don’t miss out on this chance to stay ahead in the field—dive into the full article to learn more!

#SyenzaNews #pharmaceuticals #innovation #MarketAccess

Could a landmark deal make medicines more affordable for millions of Americans? 💊

Johnson & Johnson’s medicine access agreement with the U.S. government removes tariffs, adds medicines to TrumpRx.gov for deep discounts, and aligns U.S. pricing with other developed markets. Paired with a $55B U.S. investment in manufacturing and R&D, the plan aims to create jobs, onshore advanced therapies, and reshape market access, HEOR and pricing strategies across oncology and immunology.

Read the full article to understand what this means for patients, payers and the future of U.S. pharmaceutical innovation.

#SyenzaNews #pharmaceuticals #HealthEconomics #MarketAccess #healthcarepolicy

Could higher QALY thresholds unlock faster access to innovative NHS treatments? 🔍

NICE will raise its cost‑effectiveness range to £25,000–£35,000 per QALY from April 2026, a shift expected to enable around 3–5 additional medicine approvals a year—easing market access for therapies that deliver meaningful patient benefit while preserving appraisal rigour and HST flexibility. Paired with an updated EQ‑5D‑5L value set, this change could reshape HEOR, pricing strategy, and real‑world evidence generation across the UK life sciences sector.

Read the full article to understand what this means for pharma strategy, payers, and patient access. ➡️

#SyenzaNews #HealthEconomics #pharmaceuticals #MarketAccess #costeffectiveness

🧠 Is Africa ready to invest in its brain health for economic transformation?

The Johannesburg Communiqué emphasizes that prioritizing brain health is essential for the continent’s growth as it gears up for a workforce boom. With strategies to integrate brain health into primary care and leverage digital innovations, Africa has an opportunity to mitigate costs associated with brain disorders while enhancing productivity.

Dive into the full article to explore the year 2063 and beyond through the lens of health and economic prosperity!

#SyenzaNews #HealthEconomics #DigitalTransformation #HealthcarePolicy

Could NICE’s new guidance widen access to natalizumab for people with highly active RRMS? 🔍

NICE now recommends natalizumab (subcutaneous originator Tysabri and IV biosimilar Tyruko) for adults with highly active relapsing‑remitting MS who haven’t responded to prior DMTs or for whom cladribine is unsuitable—potentially expanding access to thousands while improving affordability via biosimilar savings. The decision is backed by RCTs, real‑world evidence and a discrete‑event simulation showing favourable clinical and cost‑effectiveness profiles.

Read the full article to explore the clinical evidence, HEOR modeling and market‑access implications for patients, payers and manufacturers. 💊

#SyenzaNews #HealthEconomics #pharmaceuticals #MarketAccess #costeffectiveness

Can cardiometabolic therapies and branded generics redefine pharma growth in Latin America? 📈

Bausch Health, led by Fernando Zarate, is scaling from a Mexico- and Colombia-focused base into a regional top-ten contender by combining branded generics, vitamins, and a new cardiometabolic unit (GLP‑1s, anti‑obesity) with local manufacturing and omnichannel market access. Their mix of HEOR-driven strategy, talent investment, and targeted launches aims to improve patient access and long-term cost outcomes across the region.

Read the full interview to learn the tactics and market implications driving this expansion.

#SyenzaNews #pharmaceuticals #HealthEconomics #MarketAccess #innovation

🌟 What if there was a breakthrough therapy for relapsed/refractory multiple myeloma that could change patient outcomes?

Johnson & Johnson’s recent EMA submission for teclistamab daratumumab therapy aims to enhance treatment options for adults with just one prior therapy. This innovative duo has shown promising results, significantly reducing the risks of disease progression and death.

Curious about how this therapy could reshape myeloma care? Dive into the full article for insights on its clinical benefits and implications!

#SyenzaNews #oncology #drugdevelopment #innovation

Could simplifying the U.S. childhood vaccine schedule rebuild public trust and improve health outcomes? 🔍🛡️

The CDC’s update narrows universal recommendations from 17 to 11 core diseases—aligning U.S. practice with peer nations—while keeping coverage protections and shifting several vaccines to high‑risk or shared decision-making categories to enhance transparency and uptake. The reform also reshapes HEOR, market-access, and evidence-generation priorities to support value-based decisions and long-term confidence in immunization programs.

Read the full analysis to see which vaccines were reclassified and what this means for policy, payers, and public health.

#SyenzaNews #HealthEconomics #globalhealth #healthcarepolicy #MarketAccess

💊 What if lowering drug prices was just the beginning?

Novartis has taken a bold step with the US government, reaching an agreement to lower prices for innovative medicines while committing to expand its manufacturing and research infrastructure in the US. This pact not only aligns with national priorities but also aims to enhance patient access to critical treatments for conditions like multiple sclerosis and lung cancer.

Curious to see how this could reshape the future of healthcare? Click to explore the full details!

#SyenzaNews #pharmaceuticals #healthcare #innovation

Could mRNA and needle‑free vaccines finally make lifesaving protection truly global? 🌍

Experts say next‑gen mRNA platforms, microneedle patches and mucosal delivery could extend protection beyond COVID‑19 to RSV, enteric diseases and even therapeutic HIV strategies — while local manufacturing, AI‑driven trials and new delivery tech improve access and economic sustainability for low‑ and middle‑income countries.

Read the full expert roundup to understand the innovations, trial progress, and policy steps healthcare leaders should prioritize. 💉

#SyenzaNews #globalhealth #HealthEconomics #healthcarepolicy #innovation

🌍 How can Africa transform its healthcare landscape and ensure access to quality medicines?

The newly launched 10-year roadmap by the WHO Regional Office for Africa aims to tackle the continent’s dependency on imported medicines and improve local production capabilities. By fostering regulatory harmonization and equitable procurement, this initiative is set to reduce costs and enhance medicine security across member states.

Dive deeper into how this roadmap not only addresses current healthcare challenges but also creates economic opportunities for the region.

#SyenzaNews #HealthEconomics #HealthcareInnovation #UniversalHealthCoverage

Who will steer Portugal’s medicines regulator into 2026?

The Council of Ministers has appointed Rui dos Santos Ivo (President), Raquel Ascenção (Vice‑President) and Eduardo Costa (Board Member), bringing EMA leadership, clinical pharmacology and health‑economics expertise to INFARMED’s oversight and HTA work. Their combined profiles and the transparent, law‑based selection process are likely to shape HEOR, reimbursement decisions and Portugal’s alignment with EU HTA initiatives.

Read the full piece to see the legal framework, bios and what this leadership means for market access and regulatory strategy 🔍

#SyenzaNews #regulatoryaffairs #HealthEconomics #MarketAccess #healthcarepolicy